Skip to main content
Medical information Clinical review pending

Genetic Testing

CDH15 Gene Mental Retardation Autosomal Dominant Type 3 Genetic Test

Genetic test using Next Generation Sequencing (NGS) to detect mutations in the CDH15 gene, associated with certain types of intellectual disability and neurological disorders. Helps identify genetic causes for informed medical decisions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube). Confirm with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
A clinical history assessment and genetic counseling session, including a family pedigree chart, are recommended before the test. Follow any specific instructions provided by the laboratory or your doctor.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the CDH15 Gene Mental Retardation Autosomal Dominant Type 3 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with unexplained intellectual disability or developmental delay.
  • ✓Family history of CDH15-related disorders.
  • ✓Patients with specific neurological symptoms suggestive of CDH15 mutations.
  • ✓Genetic counseling for family planning.
  • ✓Confirmation of suspected diagnosis based on clinical features.
02

In plain language

What this test helps you understand

This test helps identify mutations in the CDH15 gene, which are linked to a specific form of autosomal dominant intellectual disability. Identifying these mutations can confirm a diagnosis, provide information for genetic counseling, and potentially guide management strategies.
The CDH15 Gene Mental Retardation Autosomal Dominant Type 3 NGS Genetic DNA Test is an advanced diagnostic tool that uses Next Generation Sequencing (NGS) technology. This test looks for specific changes (mutations) in the CDH15 gene. Identifying these mutations can help understand the genetic basis of certain neurological conditions and intellectual disabilities.

This test is particularly relevant for individuals showing signs of developmental delays or intellectual disabilities, or those with a family history of related conditions. Understanding the genetic cause can guide diagnosis, management, and family planning.

Results are interpreted by qualified geneticists. Discussing the findings with a healthcare provider is essential to understand their implications and any potential next steps. This information can empower individuals and families to make informed health decisions.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history assessment and genetic counseling session, including a family pedigree chart, are recommended before the test. Follow any specific instructions provided by the laboratory or your doctor.
SampleBlood sample (EDTA tube). Confirm with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) is used to analyze the CDH15 gene for mutations.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the CDH15 gene. It does not detect mutations in other genes that can cause similar conditions. A negative result does not completely rule out a genetic cause for the symptoms. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The CDH15 gene provides instructions for making a protein important for brain development and function. Mutations in this gene are associated with certain types of intellectual disability.
Individuals with developmental delays, intellectual disabilities, or a family history of related conditions may benefit from this test. Consult your doctor for guidance.
NGS technology provides high accuracy in detecting mutations within the CDH15 gene. However, limitations exist, and results should be interpreted by a qualified professional.
A geneticist will interpret the results. It is crucial to discuss the findings with your doctor or a genetic counselor to understand the implications and next steps.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
You can book the test by calling or WhatsApping us at +254711564616. Our team will assist you with scheduling and any inquiries.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp